Galera Therapeutics Faces Nasdaq Delisting Warning
Ticker: GRTX · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1563577
Sentiment: bearish
Topics: delisting, compliance, nasdaq
TL;DR
Nasdaq's warning Galera Therapeutics might get delisted by Nov 27. Need to fix it or bye-bye.
AI Summary
Galera Therapeutics, Inc. announced on May 31, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has 180 days, until November 27, 2024, to regain compliance. Failure to do so could lead to the delisting of its common stock from Nasdaq.
Why It Matters
This notice signals potential delisting from Nasdaq, which could significantly impact the liquidity and trading of Galera Therapeutics' stock.
Risk Assessment
Risk Level: high — The company has received a notice of non-compliance with Nasdaq listing rules, putting its stock at risk of delisting.
Key Numbers
- 180 days — Compliance Period (Timeframe to regain Nasdaq listing compliance)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Listing Exchange
- May 31, 2024 (date) — Date of Notice
- November 27, 2024 (date) — Compliance Deadline
FAQ
What specific Nasdaq listing rule(s) did Galera Therapeutics fail to meet?
The filing does not specify the exact listing rule(s) that Galera Therapeutics failed to meet, only that a notice of non-compliance was received.
What is the deadline for Galera Therapeutics to regain compliance with Nasdaq listing standards?
Galera Therapeutics has until November 27, 2024, to regain compliance with the Nasdaq listing standards.
What are the potential consequences if Galera Therapeutics fails to regain compliance?
If Galera Therapeutics fails to regain compliance, its common stock may be delisted from the Nasdaq Stock Market.
Has Galera Therapeutics taken any steps to address the non-compliance issues?
The filing does not detail specific steps being taken, but it states the company intends to regain compliance.
When did Galera Therapeutics receive the notice of non-compliance?
Galera Therapeutics received the notice of non-compliance on May 31, 2024.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-06-03 07:00:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share GRTX The Nasdaq
Filing Documents
- d758518d8k.htm (8-K) — 25KB
- 0001193125-24-152343.txt ( ) — 144KB
- grtx-20240531.xsd (EX-101.SCH) — 3KB
- grtx-20240531_lab.xml (EX-101.LAB) — 18KB
- grtx-20240531_pre.xml (EX-101.PRE) — 11KB
- d758518d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GALERA THERAPEUTICS, INC. Date: June 3, 2024 By: /s/ J. Mel Sorensen, M.D. J. Mel Sorensen, M.D. President and Chief Executive Officer